Organisation paid for research Program year 2025 Source: CMS Open Payments

Advarra, Inc

Neither a doctor nor a teaching hospital

Research payments

$94,109

46 payments

Through program year 2025, Advarra, Inc is reported as receiving $94,109 in research payments, across 46 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$20,050	6
2024	Research	$24,938	13
2023	Research	$16,145	7
2021	Research	$11,516	8
2020	Research	$14,040	8
2019	Research	$7,420	4

Breakdown

Who paid Research payments · program years 2019–2025

Edwards Lifesciences Corporation $48,543 19 payments
Exelixis Inc. $30,041 18 payments
Puma Biotechnology, Inc. $12,590 7 payments
Karyopharm Therapeutics Inc. $2,620 1 payment
Celgene Corporation $315 1 payment

Studies the money was for Research payments · program years 2019–2025

The PROGRESS Trial 2021-01 $48,543 19 payments
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors $18,525 10 payments
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors $11,516 8 payments
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer (Alisca-Lung1) $9,280 5 payments
A Phase II Study of Alisertib, An Investigational Drug, in Patients With Extensive-Stage Small Cell Lung Cancer (Es-Sclc) $3,310 2 payments
Kcp-330-009 $2,620 1 payment
Celgene - Connect MDSAML $315 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.